OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Editorial Board	339
Inflammation, lipids, and pain in vulvar disease	336
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	300
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	270
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	252
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	225
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	221
Collateral lethality: A unique type of synthetic lethality in cancers	196
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	189
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	189
Adenosine receptor signalling as a driver of pulmonary fibrosis	180
The role of macrophages in asthma-related fibrosis and remodelling	170
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	168
Unfolded protein responses: Dynamic machinery in wound healing	145
Matrikines in the skin: Origin, effects, and therapeutic potential	144
Potential neonatal toxicity of new psychoactive substances	139
Non-canonical G protein signaling	137
Endothelial dysfunction as a complication of anti-cancer therapy	134
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	128
Contribution of non-selective membrane channels and receptors in epilepsy	127
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	126
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	125
Boron in cancer therapeutics: An overview	112
Cell-based therapies for vascular regeneration: Past, present and future	111
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	108

Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	108
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	102
TLR4 biased small molecule modulators	102
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	100
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	99
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	97
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	94
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	94
Dysregulation of metabolic pathways in pulmonary fibrosis	92
TAAR1 as an emerging target for the treatment of psychiatric disorders	92
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	90
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	90
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	89
Management of drug-resistant hypertension as a heterogeneous disorder	89
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	89
Editorial Board	87
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	86
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	85
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	83
Review: Sex-related differences in the treatment of cardiac arrhythmia	83
Bispecific antibodies for the treatment of neuroblastoma	82
PGRMC1: An enigmatic heme-binding protein	77
Natural products that alleviate depression: The putative role of autophagy	76
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	75
Pharmacological treatment of cardiogenic shock – A state of the art review	74
Wnt signaling: A prospective therapeutic target for chronic pain	74
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	73
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	73
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	72
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	72
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	70
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	70
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	69
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	66
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	65
Stabilizing the neural barrier – A novel approach in pain therapy	64
DNA methylation in cell plasticity and malignant transformation in liver diseases	64
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	64
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	63